Psyence Biomedical Ltd. (PBM)
Automate Your Wheel Strategy on PBM
With Tiblio's Option Bot, you can configure your own wheel strategy including PBM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PBM
- Rev/Share 0.0
- Book/Share 8.01
- PB 0.4744
- Debt/Equity 0.0
- CurrentRatio 8.09
- ROIC -0.2244
- MktCap 433645.0
- FreeCF/Share 0.0
- PFCF 0.0
- PE -9.2023
- Debt/Assets 0.0
- DivYield 0
- ROE -0.1153
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
Published: January 22, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that it adjourned its annual and special meeting of shareholders (the “Meeting”) until February 12, 2026.
Read More
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
Published: January 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement.
Read More
Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split
Published: May 01, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - May 1, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the effective date of its 1-for-7.97 share consolidation (reverse stock split) of the Company's issued and outstanding common shares.
Read More
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D.
Read More
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it will work closely with Albert P.
Read More
About Psyence Biomedical Ltd. (PBM)
- IPO Date 2021-12-10
- Website https://www.psyencebiomed.com
- Industry Biotechnology
- CEO Jody Aufrichtig
- Employees 12